Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a standard of care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small-cell lung cancer (NSCLC). EGFR mutations are relatively common in Asian patients with NSCLC, and there is an increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Shih, Jin-Yuan, Jang, Tae-Won, Liam, Chong-Kin, Yu, Yongfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107068/
https://www.ncbi.nlm.nih.gov/pubmed/33730350
http://dx.doi.org/10.1007/s12325-021-01696-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107068/
https://www.ncbi.nlm.nih.gov/pubmed/33730350
http://dx.doi.org/10.1007/s12325-021-01696-9

Ejemplares similares